Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 May 31:2017:bcr2017219998.
doi: 10.1136/bcr-2017-219998.

Linagliptin-associated blistering and ulceration

Cristina Psomadakis  1 , Naima Shahzad  2 , Jonathan Katz  2
Affiliations
Case Reports

Linagliptin-associated blistering and ulceration

Cristina Psomadakis et al. BMJ Case Rep. .

Abstract

We present the case of 60-year-old man with type 2 diabetes who developed blistering after two sequential exposures to linagliptin. Linagliptin is one of the dipeptidyl peptidase 4 (DPP-4) inhibitors, a group of oral hypoglycaemic agents used commonly for the treatment of type 2 diabetes. On the first exposure to linagliptin, he developed blisters on the hands which resolved after stopping the drug. After repeat exposure, he developed two large blisters on the left foot, which burst giving rise to secondary infection, requiring hospital admission for treatment. We discuss the latest research linking DPP-4 inhibitors with adverse skin reactions and the effect of ulcers on the morbidity and mortality of patients with diabetes. This case report highlights skin reactions as an important, rare and lesser known side effect of DPP-4 inhibitors.

Keywords: Dermatology; Diabetes; Drugs and medicines; Endocrine system; Skin.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Patient’s left foot on presentation.
Figure 2
Figure 2
Patient’s left foot 3 months after treatment.
See this image and copyright information in PMC

References

    1. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of Gliptins. Diabetes Metab Syndr Obes 2009;2:117–26. - PMC - PubMed
    1. Skandalis K, Spirova M, Gaitanis G, et al. . Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012;26:249–53. 10.1111/j.1468-3083.2011.04062.x - DOI - PubMed
    1. Aouidad I, Fite C, Marinho E, et al. . A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 2013;149:243–5. 10.1001/jamadermatol.2013.1073 - DOI - PubMed
    1. Desai S, Brinker A, Swann J, et al. . Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med 2010;170:1169–71. 10.1001/archinternmed.2010.188 - DOI - PubMed
    1. Haber R, Fayad AM, Stephan F, et al. . Department of Dermatology, Sacre Coeur Hospital, Beirut. Lebanon JAMA Dermatol 2016;152:224–6. 10.1001/jamadermatol.2015.2939 - DOI - PubMed

Publication types

MeSH terms